Lieping Chen M.D, Ph.D
Lieping Chen, M.D, Ph.D. is the United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology, Dermatology and Medicine (Medical Oncology), and Co-Director of the Cancer Immunology Program at the Yale School of Medicine. Dr. Chen studies lymphocyte costimulation and coinhibition and their application in treating human diseases.
Dr. Chen co-discovered the PD-1/PD-L1 pathway and singularly established the PD-1/PD-L1 pathway as a target for cancer immunotherapy in 1999-2002. He initiated and organized the first human clinical trial of anti-PD-1 antibody for treating human cancer in 2006 and developed PD-L1 staining as a biomarker to predict treatment outcomes. Dr. Chen’s studies have revolutionized cancer treatment. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against a broad spectrum of human cancers.
Linzhao Cheng, Ph.D
Linzhao Cheng, Ph.D. is the Edythe Harris Lucas and Clara Lucas Lynn Professor of Hematology at John Hopkins University. As a professor of medicine, oncology and gynecology/obstetrics, he is a founding member of the Stem Cell Program in the Institute for Cell Engineering at Johns Hopkins University School of Medicine. Dr. Cheng is also the associate director for basic research in the Division of Hematology.
He initiated his stem cell research career as a postdoctoral fellow, helping establish mouse pluripotent stem cell lines from primordial germ cells, a landmark study published in Nature in 1992. Since 1994, his research has focused on human stem cell biology and cell engineering. Dr. Cheng led groups within the industry and Johns Hopkins. He has published more than 78 original research papers, including those in Nature Biotechnology, Nature Medicine, Nature Genetics, Cell, Stem Cell, Blood, and Proceedings of the National Academy of Sciences. His lab currently focuses on using human stem cells for blood disease modeling and treatment.
Joseph.E. Italiano, Ph.D
Joseph.E. Italiano, Ph.D is an associate professor of medicine at Harvard Medical School and associate biologist at Brigham and Women’s Hospital. He is one of the top scientists in the field of platelet biogenesis and the first one to invent the microfluid device for large scale generation of functional platelets from megakaryocytes derived from both human embryonic stem cells and induced pluripotent stem cells. His scientific interests have long focused on megakaryocyte and platelet biology. His early research focused on using live cell microscopy to identify the basic principles of platelet production.
Haifan Lin, Ph.D
Haifan Lin, Ph.D. is the Eugene Higgins Professor of Cell Biology, and Professor of Genetics, Obstetrics, Gynecology, and Reproductive Sciences, as well as the founding director of Yale Stem Cell Center at Yale University. He is the founding dean (Adjunct) of School of Life Science and Technology at Shanghai Tech University. Dr. Lin’s work focuses on the self-renewing mechanism of stem cells, using Drosophila germline stem cells, mouse germline and embryonic stem cells, human embryonic stem cells, and Hydra stem cells as models.
He also studies germline development and stem cell-related cancers. Dr. Lin has made key contributions to the demonstration of stem cell asymmetric division, the proof of the stem cell niche theory. He is also a discoverer of a novel class of non-coding small RNAs called PIWI-interacting RNAs (piRNAs), which was hailed by the Science Magazine as one of the Ten Scientific Breakthroughs in 2006. Dr. Lin received many awards and honors, including the American Society of Andrology Lecturer Award (2008), the Ellison Medical Foundation Senior Scholar Award (2010), the NIH Director’s Pioneer Award (2010), the NIH MERIT Award (2012)
David Scadden, M.D
David T. Scadden, M.D. is the Gerald and Darlene Jordan Professor of Medicine at Harvard Medical School and Director of the Massachusetts General Hospital Center for Regenerative Medicine and Technology. He also is Co-Director of the Harvard Stem Cell Institute. Dr. Scadden’s research focuses on reconstituting immune function using the stem cells that form blood cells to fight cancer and AIDS. He is an expert in the treatment of HIV-related Kaposi’s sarcoma and B-cell lymphoma and has developed a number of new therapies for them.
Dr. Scadden received his training at the Brigham and Women’s Hospital and Dana-Farber Cancer Institute.He has received numerous honors and awards, including the Alpha Omega Alpha; Edwin C. Garvin, MD Senior Prize; Doris Duke Innovation in Clinical Research Award; the Burroughs Welcome Fund Clinical Scientist Award in Translational Research; and the Brain Tumor Society’s Alan Goldfine Leadership Chair of Research.